Conjugation of the monoclonal antibody 17-1A with the nitroacridine compound C921 with the poly-L-lysine as an intermediate agent

Archivum Immunologiae et Therapiae Experimentalis

Volumn 45, Issue 4, 1997, Pages 343-349

  Paprocka, Maria ^a   Boratyński, Janusz ^a   Duś, Danuta ^a   Kuśnierczyk, Halina ^a   Radzikowski, Czeslaw ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

1 nitroacridine; 17 1A monoclonal antibody conjugate; Human colon adenocarcinoma; Poly L lysine

Indexed keywords

ACRIDINE; MONOCLONAL ANTIBODY; POLYLYSINE;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON ADENOCARCINOMA; CYTOTOXICITY; DRUG CONJUGATION; ENZYME SPECIFICITY; GENE TARGETING; HALF LIFE TIME; NONHUMAN; STOMACH CARCINOMA;

ACRIDINES; ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; COLONIC NEOPLASMS; FLOW CYTOMETRY; HUMANS; IMMUNOTOXINS; MELANOMA; POLYLYSINE; TUMOR CELLS, CULTURED;

EID: 0030697991     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. DZIERZBICKA K., KOLODZIEJCZYK A. M., WYSOCKA-SKRZELA B. and KOLODZIEJCZYK A. S. (1994): Synthesis of muramyl dipeptyde conjugated with acridine derivatives, showing anti HIV-1 and anticancer activity. Pol. J. Chem., 68, 37 - 45.
2. DUNCAN R. (1992): Drug-polimers conjugates: potential for improved chemotherapy. Anticancer Drugs, 3, 175 - 210.
3. FRIEND D. R. and PAGBURN S. (1987): Antibody directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 77, 4539 - 4543.
4. GUPTA P. (1990): Drug targeting in cancer chamotherapy: a clinical perspective. J. Pharm. Sci., 11, 949 - 962.
5. HERLYN D. and KOPROWSKI H. (1982): IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA, 79, 4761 - 4765.
6. MACII J. P. and PELEGRIN A. (1991): Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr. Opin. Immunol., 3, 685 - 693.
7. MOSMANN T. (1983): Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55 - 63.
8. PAPROCKA M., WIȨDLOCHA A., WALZEL H. and RADZIKOWSKI C. (1992): The activity of two immunotoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA). Arch. Immunol. Ther. Exp., 40, 223 - 227.
9. SEDLACEK H. H., SCHULTZ G., STEINSTRAESSER A., KUHLMANN L., SCHWARC Z., SEIDEL L., SEEMANN G., KRAMER H. and BOSSLET K. (1988): Monoclonal antibodies in tumor therapy. In ECKHARDT S., HOLZNER J. H. and NAGEL G. A. (eds.): Contributions to oncology, no. 2, Karge, Basel - München - Paris, pp. 1 - 19, 81 - 100.
10. WIȨDLOCHA A., SALWA J., PAPROCKA M., STEUDEN J. and RADZIKOWSKI C. (1989): Specific killing of mouse leukemic cells with ricin A-chain immunotoxin. Arch. Immunol. Ther. Exp., 37, 101 - 113.
11. YOULE R. J. and NEVILLE D. M. (1980): Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell type specific toxin. Proc. Natl. Acad. Sci. USA, 77, 5483 - 5488.